Cargando…

A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder

OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Yajuan, Xie, Hang, Shao, Hui, Cheng, Gesheng, Wang, Xingye, He, Xumei, Lan, Beidi, He, Lu, Zhang, Yushun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110699/
https://www.ncbi.nlm.nih.gov/pubmed/35592394
http://dx.doi.org/10.3389/fcvm.2022.849459
_version_ 1784709158084280320
author Du, Yajuan
Xie, Hang
Shao, Hui
Cheng, Gesheng
Wang, Xingye
He, Xumei
Lan, Beidi
He, Lu
Zhang, Yushun
author_facet Du, Yajuan
Xie, Hang
Shao, Hui
Cheng, Gesheng
Wang, Xingye
He, Xumei
Lan, Beidi
He, Lu
Zhang, Yushun
author_sort Du, Yajuan
collection PubMed
description OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel biodegradable occluders (NBOs) to achieve PFO closure. We aimed to evaluate the role of transesophageal echocardiography (TEE) in the diagnostic and anatomical evaluation of PFO, as well as in the Post-procedural assessment after transcatheter closure with a NBO. METHODS: We conducted a prospective, single-center clinical study of 44 patients who were diagnosed with PFO by contrast transthoracic echocardiography (c-TTE) and TEE from June 2019 to June 2020. All patients underwent PFO occlusion with NBO under TTE guidance. Follow-up was performed at 2 days and 3 months after the procedure with TTE, and at 6 months and 1 year after the procedure with c-TTE, TTE, and TEE. RESULTS: Interventional treatment was successfully performed in all patients. The left and right sides of the occluder device disc were significantly reduced at 3, 6, and 12 months compared to 2 days after the procedure (all P < 0.01), and decreased gradually. The thickness was significantly reduced at 12 months compared to the first three time points (all P < 0.01). Thrombus was found on the surface of the occluder device in three patients (6.4%) at 3 and 6 months after occlusion. At 6 months after procedure, there were 3 (6.8%) cases of extensive residual right-to-left shunt (RLS), 2 (4.5%) cases of moderate shunt, and 7 (15.9%) cases of small shunts. One year after procedure, 2 (4.5%) cases had a extensive residual shunt, 6 (13.6%) cases of small shunts were confirmed to originate from pulmonary veins by TEE, and the PFO-RLS occlusion rate reached 95.5%. CONCLUSION: This study demonstrates the feasibility, safety, and effectiveness of NBO for the closure of PFO in humans, with a high rate of complete shunt closure. Accurate TEE assessment of the PFO anatomy before closure with NBO is important to ensure that the procedure remains safe and effective. Furthermore, TEE plays a crucial role in the Post-procedure follow-up.
format Online
Article
Text
id pubmed-9110699
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91106992022-05-18 A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder Du, Yajuan Xie, Hang Shao, Hui Cheng, Gesheng Wang, Xingye He, Xumei Lan, Beidi He, Lu Zhang, Yushun Front Cardiovasc Med Cardiovascular Medicine OBJECTIVE: Traditional metal alloy occluders for the closure of patent foramen ovale (PFO) may be associated with some potential complications, and may restrict the trans-septal access to the left atrium for future treatment of left-sided heart disease. Increasing attention has been paid to novel biodegradable occluders (NBOs) to achieve PFO closure. We aimed to evaluate the role of transesophageal echocardiography (TEE) in the diagnostic and anatomical evaluation of PFO, as well as in the Post-procedural assessment after transcatheter closure with a NBO. METHODS: We conducted a prospective, single-center clinical study of 44 patients who were diagnosed with PFO by contrast transthoracic echocardiography (c-TTE) and TEE from June 2019 to June 2020. All patients underwent PFO occlusion with NBO under TTE guidance. Follow-up was performed at 2 days and 3 months after the procedure with TTE, and at 6 months and 1 year after the procedure with c-TTE, TTE, and TEE. RESULTS: Interventional treatment was successfully performed in all patients. The left and right sides of the occluder device disc were significantly reduced at 3, 6, and 12 months compared to 2 days after the procedure (all P < 0.01), and decreased gradually. The thickness was significantly reduced at 12 months compared to the first three time points (all P < 0.01). Thrombus was found on the surface of the occluder device in three patients (6.4%) at 3 and 6 months after occlusion. At 6 months after procedure, there were 3 (6.8%) cases of extensive residual right-to-left shunt (RLS), 2 (4.5%) cases of moderate shunt, and 7 (15.9%) cases of small shunts. One year after procedure, 2 (4.5%) cases had a extensive residual shunt, 6 (13.6%) cases of small shunts were confirmed to originate from pulmonary veins by TEE, and the PFO-RLS occlusion rate reached 95.5%. CONCLUSION: This study demonstrates the feasibility, safety, and effectiveness of NBO for the closure of PFO in humans, with a high rate of complete shunt closure. Accurate TEE assessment of the PFO anatomy before closure with NBO is important to ensure that the procedure remains safe and effective. Furthermore, TEE plays a crucial role in the Post-procedure follow-up. Frontiers Media S.A. 2022-05-03 /pmc/articles/PMC9110699/ /pubmed/35592394 http://dx.doi.org/10.3389/fcvm.2022.849459 Text en Copyright © 2022 Du, Xie, Shao, Cheng, Wang, He, Lan, He and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Du, Yajuan
Xie, Hang
Shao, Hui
Cheng, Gesheng
Wang, Xingye
He, Xumei
Lan, Beidi
He, Lu
Zhang, Yushun
A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title_full A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title_fullStr A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title_full_unstemmed A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title_short A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder
title_sort prospective, single-center, phase i clinical trial to evaluate the value of transesophageal echocardiography in the closure of patent foramen ovale with a novel biodegradable occluder
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110699/
https://www.ncbi.nlm.nih.gov/pubmed/35592394
http://dx.doi.org/10.3389/fcvm.2022.849459
work_keys_str_mv AT duyajuan aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT xiehang aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT shaohui aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT chenggesheng aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT wangxingye aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT hexumei aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT lanbeidi aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT helu aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT zhangyushun aprospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT duyajuan prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT xiehang prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT shaohui prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT chenggesheng prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT wangxingye prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT hexumei prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT lanbeidi prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT helu prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder
AT zhangyushun prospectivesinglecenterphaseiclinicaltrialtoevaluatethevalueoftransesophagealechocardiographyintheclosureofpatentforamenovalewithanovelbiodegradableoccluder